Published in Brain Res on March 20, 1999
Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A (2004) 3.21
Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain (2008) 2.55
The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J Physiol (2007) 2.13
Extrasynaptic alphabeta subunit GABAA receptors on rat hippocampal pyramidal neurons. J Physiol (2006) 1.60
A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology (2011) 1.38
Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience (2013) 1.17
Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol (2011) 1.16
Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology (2012) 1.10
Molecular aspects of age-related cognitive decline: the role of GABA signaling. Trends Mol Med (2015) 1.06
An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology (Berl) (2006) 1.04
Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol (2004) 1.00
Gene expression analysis of the embryonic subplate. Cereb Cortex (2011) 0.98
A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. Int J Med Chem (2015) 0.88
Effects of post-training hippocampal injections of midazolam on fear conditioning. Learn Mem (2005) 0.86
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Adv Pharmacol Sci (2011) 0.85
Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition. J Pharmacol Exp Ther (2010) 0.84
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr Bull (2014) 0.84
alpha5 Subunit-containing GABA(A) receptors mediate a slowly decaying inhibitory synaptic current in CA1 pyramidal neurons following Schaffer collateral activation. Neuropharmacology (2009) 0.83
The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia. Curr Pharm Des (2014) 0.81
Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease. Neurotherapeutics (2017) 0.80
Benzodiazepine-induced spatial learning deficits in rats are regulated by the degree of modulation of α1 GABA(A) receptors. Eur Neuropsychopharmacol (2012) 0.77
γ-Aminobutyric acid neural signaling in the lateroanterior hypothalamus modulates aggressive behavior in adolescent anabolic/androgenic steroid-treated hamsters. Behav Pharmacol (2014) 0.77
New insights in the systemic and molecular underpinnings of general anesthetic actions mediated by γ-aminobutyric acid A receptors. Curr Opin Anaesthesiol (2016) 0.76
Molecular mechanisms of general anesthesia. Korean J Anesthesiol (2010) 0.75
Enhancement of α5-containing γ-aminobutyric acid type A receptors by the nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6) is abolished by the β3(N265M) mutation. Anesth Analg (2014) 0.75
Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives. Biol Psychiatry (2017) 0.75
Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects. Int J Neuropsychopharmacol (2017) 0.75
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci (2000) 5.53
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
Ligand-gated ion channel subunit partnerships: GABAA receptor alpha6 subunit gene inactivation inhibits delta subunit expression. J Neurosci (1997) 2.08
Preferential coassembly of alpha4 and delta subunits of the gamma-aminobutyric acidA receptor in rat thalamus. Mol Pharmacol (1999) 1.96
Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann N Y Acad Sci (1999) 1.71
theta, a novel gamma-aminobutyric acid type A receptor subunit. Proc Natl Acad Sci U S A (1999) 1.54
Another mechanism for creating diversity in gamma-aminobutyrate type A receptors: RNA splicing directs expression of two forms of gamma 2 phosphorylation site. Proc Natl Acad Sci U S A (1990) 1.53
alpha4beta3delta GABA(A) receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential. J Biol Chem (2001) 1.48
Structure and pharmacology of vertebrate GABAA receptor subtypes. Int Rev Neurobiol (1995) 1.42
A novel allosteric modulatory site on the GABAA receptor beta subunit. Neuron (1994) 1.41
Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer. J Biol Chem (1999) 1.41
Inositol monophosphatase inhibitors: a novel treatment for bipolar disorder? Biol Psychiatry (1995) 1.39
Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. J Neurosci (2001) 1.37
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
Structure of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci U S A (1992) 1.32
Cerebrospinal fluid production is reduced in healthy aging. Neurology (1990) 1.31
Age-related changes in GABA(A) receptor subunit composition and function in rat auditory system. Neuroscience (1999) 1.29
An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther (2005) 1.28
Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther (2000) 1.26
Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol (2001) 1.26
cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme. Biochem J (1992) 1.23
[3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacology (1996) 1.21
Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci U S A (1994) 1.18
Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur J Neurosci (2006) 1.13
Tyrosine kinase phosphorylation of GABAA receptors. Brain Res Mol Brain Res (1995) 1.11
Metabolism of alpha- and beta-adrenergic receptors in vitro and in vivo. Annu Rev Pharmacol Toxicol (1987) 1.09
Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form. Neurosci Lett (1983) 1.05
An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology (Berl) (2006) 1.04
Model of subunit composition of gamma-aminobutyric acid A receptor subtypes expressed in rat cerebellum with respect to their alpha and gamma/delta subunits. J Biol Chem (1994) 1.01
Structural studies of metal binding by inositol monophosphatase: evidence for two-metal ion catalysis. Biochemistry (1994) 1.00
Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem (1986) 1.00
MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J Psychopharmacol (2010) 0.99
Probing the role of metal ions in the mechanism of inositol monophosphatase by site-directed mutagenesis. Eur J Biochem (1993) 0.98
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. J Psychopharmacol (2010) 0.97
Structural analysis of inositol monophosphatase complexes with substrates. Biochemistry (1994) 0.96
Stable expression of mammalian type A gamma-aminobutyric acid receptors in mouse cells: demonstration of functional assembly of benzodiazepine-responsive sites. Proc Natl Acad Sci U S A (1992) 0.96
Characterisation of delta-subunit containing GABAA receptors from rat brain. Eur J Pharmacol (1995) 0.96
Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharm Drug Dispos (2005) 0.96
Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors. Neuropsychopharmacology (1999) 0.95
Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology (1988) 0.93
Localization of 5-HT3 receptors in the rat spinal cord: immunohistochemistry and in situ hybridization. Neuroreport (1995) 0.92
Alpha2-containing GABA(A) receptors are involved in mediating stimulant effects of cocaine. Pharmacol Biochem Behav (2008) 0.91
The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. Brain Res (1990) 0.91
CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res (1992) 0.89
Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type. J Neurol Sci (1985) 0.89
Retinoic acid evoked-differentiation of neuroblastoma cells predominates over growth factor stimulation: an automated image capture and quantitation approach to neuritogenesis. Anal Biochem (2001) 0.88
Cell surface expression of the human N-methyl-D-aspartate receptor subunit 1a requires the co-expression of the NR2A subunit in transfected cells. Neuroscience (1996) 0.88
CSF and serum concentrations of albumin and IgG in Alzheimer's disease. Neurobiol Aging (1987) 0.88
Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer's disease patients. Neuroscience (2000) 0.88
Differential subcellular distribution of the alpha 6 subunit versus the alpha 1 and beta 2/3 subunits of the GABAA/benzodiazepine receptor complex in granule cells of the cerebellar cortex. Neuroscience (1992) 0.88
Evidence for a membrane lipid defect in Alzheimer disease. Mol Chem Neuropathol (1993) 0.88
Heterogeneity of mammalian alpha 2-adrenoceptors delineated by [3H]yohimbine binding. Eur J Pharmacol (1986) 0.85
Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FEBS Lett (1988) 0.85
Dopaminergic system activity and cellular defense mechanisms in the striatum and striatal synaptosomes of the rat subchronically exposed to manganese. Arch Toxicol (1994) 0.84
Glutathione deficiency potentiates manganese toxicity in rat striatum and brainstem and in PC12 cells. Pharmacol Res (1997) 0.84
gamma-Aminobutyric acid type A receptors in the rat brain can contain both gamma 2 and gamma 3 subunits, but gamma 1 does not exist in combination with another gamma subunit. Mol Pharmacol (1994) 0.83
Compartmentation of alpha 2-adrenergic receptors in human erythroleukemia (HEL) cells. Mol Pharmacol (1987) 0.83
Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett (1988) 0.83
Physostigmine treatment of progressive supranuclear palsy. Ann Neurol (1989) 0.82
Changes in [3H]zolpidem and [3H]Ro 15-1788 binding in rat globus pallidus and substantia nigra pars reticulata following a nigrostriatal tract lesion. Brain Res (2000) 0.82
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol (1994) 0.82
[3H]MK-801 binding to N-methyl-D-aspartate receptors solubilized from rat brain: effects of glycine site ligands, polyamines, ifenprodil, and desipramine. J Neurochem (1991) 0.81
Evidence that porcine native 5-HT3 receptors do not contain nicotinic acetylcholine receptor subunits. Neuropharmacology (1998) 0.81
Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features. Neurology (1988) 0.81
Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J Neurochem (1987) 0.81
Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved? Trends Pharmacol Sci (2001) 0.81
Regional specificity of membrane instability in Alzheimer's disease brain. Brain Res (1993) 0.81
Measurement of alpha-adrenoceptor "turnover' using phenoxybenzamine. Eur J Pharmacol (1982) 0.81
Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci Lett (1993) 0.80
Neocortical cholinergic enzyme and receptor activities in the human fetal brain. J Neurochem (1986) 0.80
Allopurinol protects against manganese-induced oxidative stress in the striatum and in the brainstem of the rat. Neurosci Lett (1995) 0.80
Effects of ageing on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat. Neurosci Lett (1993) 0.79
Effects of morphine treatment and withdrawal on striatal and limbic monoaminergic activity and ascorbic acid oxidation in the rat. Brain Res (1996) 0.79
Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. J Neurochem (1984) 0.79
Lumbar cerebrospinal fluid choline in healthy aging and in Down's syndrome. Arch Neurol (1990) 0.78
Generation and characterisation of stable cell lines expressing recombinant human N-methyl-D-aspartate receptor subtypes. J Neurochem (1996) 0.78
Synthesis and anticholinesterase activity of (-)-N1-norphysostigmine, (-)-eseramine, and other N(1)-substituted analogues of (-)-physostigmine. J Med Chem (1988) 0.78
The effects of cortical ablation on d-amphetamine-induced changes in striatal dopamine turnover and ascorbic acid catabolism in the rat. Neurosci Lett (1992) 0.78
Immunohistochemical localization of intracellular plasma proteins in the human central nervous system. Acta Neuropathol (1989) 0.78
Characterization of [35S]t-butylbicyclophosphorothionate ([35S]TBPS) binding to GABAA receptors in postmortem human brain. Br J Pharmacol (2007) 0.78
Effect of morphine on striatal dopamine metabolism and ascorbic and uric acid release in freely moving rats. Brain Res (1997) 0.78
Differential expression of cytochrome oxidase (COX) genes in different regions of monkey brain. J Neurosci Res (1992) 0.78
GABA(A) alpha 1 subunit knock-out mice do not show a hyperlocomotor response following amphetamine or cocaine treatment. Neuropharmacology (2003) 0.78
Cellular defence mechanisms in the striatum of young and aged rats subchronically exposed to manganese. Neuropharmacology (1995) 0.78
Clorgyline and desipramine alter the sensitivity of [3H]noradrenaline release to calcium but not to clonidine. Brain Res (1986) 0.77
Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging. Neuropharmacology (2010) 0.77
Investigations into the relationship between the dopaminergic system and ascorbic acid in rat striatum. Neurosci Lett (1991) 0.77
Monoclonal antibodies to the human gamma 2 subunit of the GABAA/benzodiazepine receptors. J Neurochem (1995) 0.77
Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem (1987) 0.76
pp60c-src kinase expression in brain of adult rats in relation to age. Exp Gerontol (1990) 0.76
Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Ann Neurol (1988) 0.76